CN110062625A - 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法 - Google Patents

尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法 Download PDF

Info

Publication number
CN110062625A
CN110062625A CN201780076503.9A CN201780076503A CN110062625A CN 110062625 A CN110062625 A CN 110062625A CN 201780076503 A CN201780076503 A CN 201780076503A CN 110062625 A CN110062625 A CN 110062625A
Authority
CN
China
Prior art keywords
nintedanib
pharmaceutical composition
pharmaceutical
inhibitor
interstitial lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780076503.9A
Other languages
English (en)
Chinese (zh)
Inventor
S·沃林
E·韦克斯
F·赫尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN110062625A publication Critical patent/CN110062625A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201780076503.9A 2016-12-12 2017-12-06 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法 Pending CN110062625A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16203359 2016-12-12
EP16203359.1 2016-12-12
PCT/EP2017/081691 WO2018108669A1 (en) 2016-12-12 2017-12-06 Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol

Publications (1)

Publication Number Publication Date
CN110062625A true CN110062625A (zh) 2019-07-26

Family

ID=57544282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780076503.9A Pending CN110062625A (zh) 2016-12-12 2017-12-06 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法

Country Status (5)

Country Link
US (1) US20200069679A1 (https=)
EP (1) EP3551187B1 (https=)
JP (1) JP2019536812A (https=)
CN (1) CN110062625A (https=)
WO (1) WO2018108669A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114617860A (zh) * 2020-12-14 2022-06-14 南京华威医药科技集团有限公司 一种含尼达尼布的吸入液及其制备方法
CN114869866A (zh) * 2022-05-05 2022-08-09 珠海瑞思普利医药科技有限公司 一种治疗特发性肺纤维化的干粉吸入剂及其制备方法
CN116390730A (zh) * 2021-09-15 2023-07-04 参天制药株式会社 用于预防和/或治疗干眼症的药剂
CN119857088A (zh) * 2025-01-22 2025-04-22 杭州畅溪制药有限公司 复方吸入粉雾剂及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
FI3761980T3 (fi) 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
EP3841090A4 (en) * 2018-08-22 2022-10-19 Avalyn Pharma Inc. SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS
CA3197627A1 (en) * 2020-11-18 2022-05-27 Kimberly SHEPARD Inhalable dry powder formulations comprising angiogenesis inhibitors
CN114642656B8 (zh) * 2020-12-18 2025-12-12 盈科瑞（天津）创新医药研究有限公司 一种吸入用尼达尼布溶液及其制备方法
JP2025523707A (ja) * 2022-05-28 2025-07-23 アヴァリン ファーマ インク． ニンテダニブおよびニンテダニブの組み合わせ乾燥粉末組成物と使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140100222A1 (en) * 2012-10-09 2014-04-10 Boehringer Ingelheim International Gmbh Beta2-ADRENOCEPTOR AGONIST FOR THE TREATMENT OF COUGH

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE102004019539A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004024452A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
DE102004024451A1 (de) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
BRPI0614410A2 (pt) 2005-08-15 2011-03-29 Boehringer Ingelheim Int processo para preparação de betamiméticos
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
US20070088030A1 (en) 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
AR065017A1 (es) 2007-01-25 2009-05-13 Boehringer Ingelheim Int Procedimiento para la preparacion de betamimeticos
UA104590C2 (ru) 2008-06-06 2014-02-25 Берингер Ингельхайм Интернациональ Гмбх Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
WO2010057927A1 (en) 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
US20110281858A1 (en) 2008-11-21 2011-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140100222A1 (en) * 2012-10-09 2014-04-10 Boehringer Ingelheim International Gmbh Beta2-ADRENOCEPTOR AGONIST FOR THE TREATMENT OF COUGH

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RICHELDI ETAL.: "Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis", 《NEW ENGLAND JOURNAL OF MEDICINE》 *
STN CAS: "656247-18-6", 《STN REG》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114617860A (zh) * 2020-12-14 2022-06-14 南京华威医药科技集团有限公司 一种含尼达尼布的吸入液及其制备方法
CN116390730A (zh) * 2021-09-15 2023-07-04 参天制药株式会社 用于预防和/或治疗干眼症的药剂
US12005063B2 (en) 2021-09-15 2024-06-11 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye
CN114869866A (zh) * 2022-05-05 2022-08-09 珠海瑞思普利医药科技有限公司 一种治疗特发性肺纤维化的干粉吸入剂及其制备方法
CN114869866B (zh) * 2022-05-05 2024-02-20 珠海瑞思普利医药科技有限公司 一种治疗特发性肺纤维化的干粉吸入剂及其制备方法
CN119857088A (zh) * 2025-01-22 2025-04-22 杭州畅溪制药有限公司 复方吸入粉雾剂及其制备方法

Also Published As

Publication number Publication date
WO2018108669A1 (en) 2018-06-21
US20200069679A1 (en) 2020-03-05
JP2019536812A (ja) 2019-12-19
EP3551187B1 (en) 2021-02-17
EP3551187A1 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
EP3551187B1 (en) Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
US11975005B2 (en) Treatment of respiratory diseases
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
US9700564B2 (en) Use of aerosolized levofloxacin for treating cystic fibrosis
CN100352442C (zh) 药物组合
CN105101999A (zh) 用在病毒性疾病的治疗中的mek抑制剂
JP2007314517A (ja) ロキソプロフェンを含有する鎮咳又は去痰のための医薬組成物
JP2005513031A (ja) 肺線維症の処置のためのｐｐａｒアクチベーターの使用
BG107596A (bg) Фармацевтичен състав на салметерол и флутиказон пропионат
EP4192457B1 (en) Compositions comprising ketotifen and a non-steroidal anti-inflammatory drug selected from naproxen or indomethacin for use in the treatment of a beta coronavirus infection
JP7745571B2 (ja) 肺線維症を処置する方法
CN116033900A (zh) 治疗冠状病毒暴露所致疾病的方法
US11154621B2 (en) Liponucleotide-based therapy for COPD
AU2003292120A1 (en) New synergistic combination comprising roflumilast and formoterol
SK8572003A3 (en) Histamine receptor antagonists
JP2023553290A (ja) 慢性閉塞性肺疾患、喘息、肺炎、気管支炎、嚢胞性線維症、肺水腫、間質性肺疾患、サルコイドーシス、特発性肺胞線維症、急性呼吸窮迫症候群、および肺動脈性肺高血圧症を治療するための方法および組成物
EA025224B1 (ru) ПРИМЕНЕНИЕ 3-ЭТОКСИ-6-{2-[1-(6-МЕТИЛПИРИДАЗИН-3-ИЛ)ПИПЕРИДИН-4-ИЛ]ЭТОКСИ}БЕНЗО[d]ИЗОКСАЗОЛА ИЛИ ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ПРИ ЛЕЧЕНИИ ИЛИ ОБЛЕГЧЕНИИ СИМПТОМОВ АСТМЫ
WO2022215616A1 (ja) コロナウイルス感染症治療剤
US20210353563A1 (en) Composition and method for treatment of respiratory disorders
JP2023503723A (ja) 好酸球性喘息の処置のためのｍａｓｉｔｉｎｉｂの使用
EA009990B1 (ru) Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол
WO2007126001A1 (ja) ロキソプロフェンを含有する鎮咳又は去痰のための医薬組成物
US20240009214A1 (en) Method of Treating Viral Infection
JP2009007332A (ja) アゼラスチン類とエフェドリン類を含有する医薬組成物
TW202045184A (zh) 預防或治療肺纖維化的藥物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190726

WD01 Invention patent application deemed withdrawn after publication